Research Progress on Multiple Myeloma with Extramedullary Disease.
10.7534/j.issn.1009-2137.2016.03.057
- Author:
Lu WANG
1
;
Yi-Zhuo ZHANG
2
Author Information
1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
2. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. E-mail: 18622221239@163.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow;
pathology;
Humans;
Multiple Myeloma;
pathology;
Plasma Cells;
pathology;
Prognosis
- From:
Journal of Experimental Hematology
2016;24(3):945-948
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a malignancy of terminally differentiated monoclonal B cells, which is characterized by the presentation of malignant plasma cell within the bone marrow and the secretion of monoclonal immunoglobulin. Extramedullary disease (EMD) may be found either at diagnosis or during therapy of these patients. For the patients with EMD, the response to conventional chemotherapy is poor and the prognosis is unfavorable. This review mainly discusses the research progress in the pathogenesis, the clinical feature, the therapy and the prognosis of MM with EMD.
